{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.8","upperLimit":"40.7","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"OR: confirmed stringent complete response(sCR),complete response(CR),very good partial response(VGPR) or partial response(PR) as per International Myeloma Working Group Uniform Response Criteria (IMWGURC). sCR: normal serum free light chain (FLC) ratio, absence of clonal cells in bone marrow. CR: disappearance of any soft tissue plasmacytomas, \\<5 percent (%) plasma cells in bone marrow, negative immunofixation on serum, urine. VGPR: serum, urine M-protein detectable by immunofixation but not on electrophoresis, \\>= 90% reduction in serum M-protein, \\<100 mg/24 hour (hr) urine M-protein. PR: \\>=50% reduction in serum M-protein, reduction in 24-hr urinary M-protein by \\>=90% or to \\<200 mg/24 hr, \\>=50% decrease in difference between involved and uninvolved FLC levels if serum, urine M-protein were unmeasurable, \\>= 50% reduction in plasma cells, provided baseline bone marrow plasma cell was \\>=30% if serum, urine M-protein were unmeasurable and serum free light assay was unmeasureable.","dispersionType":"95% Confidence Interval","groups":[{"description":"Palbociclib (PD 0332991) 100 mg capsule orally once daily for 12 days followed by 9 days off-treatment in a 21-day cycle along with bortezomib 1.0 mg/m\\^2 intravenous injection and dexamethasone 20 mg tablet orally 30 minutes prior to bortezomib injection on Day 8, 11, 15 and 18 of 21-day cycle (schedule B) during Phase 2 of the study. Treatment was continued until any of the following withdrawal criteria was met: disease progression (unless the investigator judged that participant could still derive clinical benefit from continuing the treatment and the risk/benefit was still favorable), unacceptable toxicities, need for surgery or radiation therapy considered due to progressive disease by investigator, investigator conclusion that it is in the participant's best interest to discontinue therapy, need for anti-cancer therapy, lost to follow-up, withdrawal from treatment, or withdrawal of consent.","id":"OG000","title":"Palbociclib 100mg+Bortezomib+Dexamethasone(Phase2:ScheduleB)"}],"paramType":"NUMBER","populationDescription":"Primary response analysis set (PRAS) included first consecutive (by first treatment day) participants in response analysis set (RAS=included all enrolled participants who received study treatment, had an adequate baseline tumor assessment and measurable disease) that were response-evaluable.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 (baseline) up to end of study (up to cycle 22 for schedule B)","title":"Percentage of Participants With Objective Response (OR): Phase 2","type":"PRIMARY","unitOfMeasure":"percentage of participants"}